Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABL503 in Advanced Solid Tumors
NCT04762641Phase 1Recruiting
- Sponsor
- ABL Bio
- Start
- Apr 2021
- Primary completion
- Nov 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of TJ-L14B + ABL503 in solid tumor, sponsored by ABL Bio. Primary endpoints: Dose-Limiting Toxicities and Adverse Events up to 12 months. Started Apr 2021; status: recruiting.
02
Drugs
TJ-L14B + ABL503
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04762641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762641.